ValiRx PLC (AIM:VAL) Conclusion of Evaluation Project

London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, provides the following update at the conclusion of the Evaluation project from Imperial College London announced on 21 March 2024.

On entering the collaboration agreement with Imperial College London in March 2024, the Company synthesised, tested and profiled drug candidates from the Dual Kinase series in comparison with gold standard therapeutics in a range of tests. 

Although initial results showed promise, the development programme is at an early stage, and the Company has decided to return the project to the university researchers for further development, with no further financial commitment from the Company. The parties have agreed to terminate the current collaboration agreement and revert responsibility for maintaining the intellectual property to Imperial College London.

Mark Eccleston, CEO of ValiRx commented “Working alongside the Imperial College London team on this project has been an engaging experience, and although we are not in a position to progress with this lead series of molecules at this stage, we look forward to retaining close contact with the team at Imperial to hear further updates on these and other projects which could lead to future agreements.”

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (“UK MAR”). The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact: